Sonya Marshall-Gradisnik

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Source: InvestinME

Sonya M. Marshall-Gradisnik, BSc (Hons), PhD, is director of the National Centre for Neuroimmunology and Emerging Diseases (NCNED) at Griffith University in Australia.[1] Her expertise is in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis with particular focus on Natural Killer Cell function and signalling pathways, T regulatory and B cell phenotypes and cytokine production, and transcriptional profiling and gene expression.[2] In her studies, she compares the changes of the different cells of the immune system in relation to the severity of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. Professor Marshall-Gradisnik established the first Australian CFS/ME research/medical clinic at Griffith University, which was developed in conjunction with Queensland Health and CFS public health programs and provides clinical support for patients and carers at Gold Cost University Hospital, Griffith University. Later she established a mobile CFS research clinic to ensure the most severely affected CFS patients are able to have medical attention as well as participate in research.[3]

Awards[edit | edit source]

  • Queensland Women in Technology Research Award Rising Star Award for her research into immunological biomarkers for CFS or ME in 2010[4]
  • National Award as Best Young Science Investigator at the Australian Conference for Science and Medicine for her studies into natural killer cell function and genotyping[4]
  • Finalist in Young Australian of the Year Award Science and Technology Category[4]

Committees and writing boards[edit | edit source]

International Consensus Criteria[edit | edit source]

2011 - Marshall-Gradisnik co-authored the 2011 case definition, International Consensus Criteria.[5]

International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis[edit | edit source]

Marshall-Gradisnik serves on the Board of Directors of the International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (IACFS/ME).[3]

Marshall-Gradisnik serves on the editorial board of the journal, Fatigue: Biomedicine, Health & Behavior, published on behalf of the IACFS/ME.[6]

Austrialia National Health and Medical Research Council's ME and CFS advisory committee[edit | edit source]

2018 - Prof Marshall-Gradisnik serves on the Australian government's National Health and Medical Research Council's ME and CFS advisory committee.[7]

Biomarker Patent[edit | edit source]

In 2016, Griffith University filed for a patent for a biological marker (Patent Publication number WO2016023077 A1)[7] for the diagnosis and management of ME and CFS. Sonya Marshall-Gradisnik and Ekua Brenu are listed as the inventors. The application states: "The present invention resides broadly in the use of at least one miRNA as a biological marker for identifying or diagnosing a subject having CFS and/or ME."[8]

Notable studies[edit | edit source]

  • 2022, Impaired TRPM3-dependent calcium influx and restoration using Naltrexone in natural killer cells of myalgic encephalomyelitis/chronic fatigue syndrome patients[9] - (Full text)
  • 2022, Volumetric differences in hippocampal subfields and associations with clinical measures in myalgic encephalomyelitis/chronic fatigue syndrome[10] - (Full text)
  • 2022, Alteration of Cortical Volume and Thickness in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome[11] - (Full text)
  • 2021, Potential implications of mammalian transient receptor potential melastatin 7 in the pathophysiology of myalgic encephalomyelitis/chronic fatigue syndrome: A review[12] - (Full text)
  • 2021, Network analysis of symptoms co-occurrence in chronic fatigue syndrome[13] - (Full text)
  • 2021, Impact of life stressors on myalgic encephalomyelitis/chronic fatigue syndrome symptoms: An australian longitudinal study[14] - (Full text)
  • 2021, Diffusion tensor imaging reveals neuronal microstructural changes in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome[15] - (Full text)
  • 2021, Characterization of IL-2 Stimulation and TRPM7 Pharmacomodulation in NK Cell Cytotoxicity and Channel Co-Localization with PIP2 in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients[16] - (Full text)
  • 2021, Analysis of post COVID-19 condition and its overlap with myalgic encephalomyelitis/chronic fatigue syndrome[17] - (Full text)
  • 2021, A systematic review of nutraceutical interventions for mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome[18] - (Full text)
  • 2021, A preliminary investigation of nutritional intake and supplement use in australians with myalgic encephalomyelitis/chronic fatigue syndrome and the implications on health-related quality of life[19] - (Full text)
  • 2021, The effect of IL-2 stimulation and treatment of TRPM3 on channel co-localisation with PIP2 and NK cell function in myalgic encephalomyelitis/chronic fatigue syndrome patients[20] - (Full text)
  • 2021, Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment[21] - (Full text)
  • 2021, Systematic Review of Sleep Characteristics in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome[22] - (Full text)
  • 2020, Health-related quality of life in patients with myalgic encephalomyelitis/chronic fatigue syndrome: an Australian cross-sectional study[23] - (Full text)
  • 2020, Mapping of pathological change in chronic fatigue syndrome using the ratio of T1- and T2-weighted MRI scans[24] - (Full text)
  • 2020, A systematic review of mitochondrial abnormalities in myalgic encephalomyelitis/chronic fatigue syndrome/systematic exertion intolerance disease[25][26] - (Full text), (Correction)
  • 2019, Epidemiology of paediatric chronic fatigue syndrome in Australia[27] - (Full text)
  • 2019, Prevalence and characteristics of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) in Poland: a cross-sectional study[28] - (Full text)
  • 2019, Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients[29] - (Full text)
  • 2019, A systematic review of cytokines in chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID)[30] - (Full text)
  • 2019, Naltrexone restores impaired transient receptor potential melastatin 3 ion channel function in natural killer cells from myalgic encephalomyelitis/chronic fatigue syndrome patients[31] - (Abstract)
  • 2019, Intra brainstem connectivity is impaired in chronic fatigue syndrome[32] - (Full text)
  • 2019, Transient receptor potential melastatin 2 channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients[33] - (Full text)
  • 2012, The Effects of Influenza Vaccination on Immune Function[62] - (Full Text)

Advocacy[edit | edit source]

Open Letter to The Lancet[edit | edit source]

Three open letters to the editor of The Lancet urged the editor to commission a fully independent review of the PACE trial, which the journal had published in 2011. In 2016, Dr. Marshall-Gradisnik, along with 41 colleagues in the ME/CFS field, signed the second letter. In June 2018, Dr. Marshall-Gradisnik signed the third letter, along with approximately 100 colleagues.

Clinic location[edit | edit source]

National Centre for Neuroimmunology and Emerging Diseases (NCNED) is located at Griffith University on the Gold Coast, Queensland, Australia.

Talks and interviews[edit | edit source]

Online presence[edit | edit source]

See also[edit | edit source]

News and interviews[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. ↑ "Professor Sonya Marshall-Gradisnik". Griffith University. Retrieved August 12, 2022.
  2. ↑ https://www.griffith.edu.au/health/school-medical-science/staff/professor-sonya-marshall-gradisnik
  3. ↑ 3.0 3.1 "Board Member-Sonya Marshall-Gradisnik, PhD". IACFSME. Retrieved December 7, 2018.
  4. ↑ 4.0 4.1 4.2 "Editor - Sonya Marshall-Gradisnik | Bond University | 5340". omicsonline.org. Retrieved December 7, 2018.
  5. ↑ Carruthers, Bruce M.; van de Sande, Marjorie I.; De Meirleir, Kenny L.; Klimas, Nancy G.; Broderick, Gordon; Mitchell, Terry; Staines, Donald; Powles, A.C. Peter; Speight, Nigel; Vallings, Rosamund; Bateman, Lucinda; Baumgarten-Austrheim, Barbara; Bell, David; Carlo-Stella, Nicoletta; Chia, John; Darragh, Austin; Jo, Daehyun; Lewis, Donald; Light, Alan; Marshall-Gradisnik, Sonya; Mena, Ismael; Mikovits, Judy; Miwa, Kunihisa; Murovska, Modra; Pall, Martin; Stevens, Staci (August 22, 2011). "Myalgic encephalomyelitis: International Consensus Criteria". Journal of Internal Medicine. 270 (4): 327–338. doi:10.1111/j.1365-2796.2011.02428.x. ISSN 0954-6820. PMC 3427890. PMID 21777306.
  6. ↑ "Fatigue: Biomedicine, Health & Behavior". tandfonline.com. Retrieved November 1, 2019.
  7. ↑ 7.0 7.1 "Myalgic Encephalomyelitis and Chronic Fatigue Syndrome | NHMRC". nhmrc.gov.au. Retrieved December 6, 2018.
  8. ↑ Biological markers, retrieved September 1, 2019
  9. ↑ Eaton-Fitch, Natalie; Du Preez, Stanley; Cabanas, Hélène; Muraki, Katsuhiko; Staines, Donald; Marshall-Gradisnik, Sonya (February 16, 2022). "Impaired TRPM3-dependent calcium influx and restoration using Naltrexone in natural killer cells of myalgic encephalomyelitis/chronic fatigue syndrome patients". Journal of Translational Medicine. 20 (1): 94. doi:10.1186/s12967-022-03297-8. ISSN 1479-5876. PMC 8848670. PMID 35172836.
  10. ↑ Thapaliya, Kiran; Staines, Donald; Marshall‐Gradisnik, Sonya; Su, Jiasheng; Barnden, Leighton (July 2022). "Volumetric differences in hippocampal subfields and associations with clinical measures in myalgic encephalomyelitis/chronic fatigue syndrome". Journal of Neuroscience Research. 100 (7): 1476–1486. doi:10.1002/jnr.25048. ISSN 0360-4012. PMC 9321967. PMID 35355311.
  11. ↑ Thapaliya, Kiran; Marshall-Gradisnik, Sonya; Staines, Donald; Su, Jiasheng; Barnden, Leighton (2022). "Alteration of Cortical Volume and Thickness in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". Frontiers in Neuroscience. 16. doi:10.3389/fnins.2022.848730. ISSN 1662-453X. PMC 9072664. PMID 35527811.
  12. ↑ Du Preez, Stanley; Cabanas, Helene; Staines, Donald; Marshall-Gradisnik, Sonya (January 2021). "Potential Implications of Mammalian Transient Receptor Potential Melastatin 7 in the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Review". International Journal of Environmental Research and Public Health. 18 (20): 10708. doi:10.3390/ijerph182010708. ISSN 1660-4601. PMC 8535478. PMID 34682454.
  13. ↑ Kujawski, Sławomir; Słomko, Joanna; Newton, Julia L.; Eaton-Fitch, Natalie; Staines, Donald R.; Marshall-Gradisnik, Sonya; Zalewski, Paweł (January 2021). "Network Analysis of Symptoms Co-Occurrence in Chronic Fatigue Syndrome". International Journal of Environmental Research and Public Health. 18 (20): 10736. doi:10.3390/ijerph182010736. ISSN 1660-4601. PMC 8535251. PMID 34682478.
  14. ↑ Balinas, Cassandra; Eaton-Fitch, Natalie; Maksoud, Rebekah; Staines, Donald; Marshall-Gradisnik, Sonya (January 2021). "Impact of Life Stressors on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Symptoms: An Australian Longitudinal Study". International Journal of Environmental Research and Public Health. 18 (20): 10614. doi:10.3390/ijerph182010614. ISSN 1660-4601. PMC 8535742. PMID 34682360.
  15. ↑ Thapaliya, Kiran; Marshall‐Gradisnik, Sonya; Staines, Donald; Barnden, Leighton (September 2021). "Diffusion tensor imaging reveals neuronal microstructural changes in myalgic encephalomyelitis/chronic fatigue syndrome". European Journal of Neuroscience. 54 (6): 6214–6228. doi:10.1111/ejn.15413. ISSN 0953-816X. PMC 9291819. PMID 34355438.
  16. ↑ Du Preez, Stanley; Eaton-Fitch, Natalie; Cabanas, Helene; Staines, Donald; Marshall-Gradisnik, Sonya (January 2021). "Characterization of IL-2 Stimulation and TRPM7 Pharmacomodulation in NK Cell Cytotoxicity and Channel Co-Localization with PIP2 in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients". International Journal of Environmental Research and Public Health. 18 (22): 11879. doi:10.3390/ijerph182211879. ISSN 1660-4601. PMC 8618557. PMID 34831634.
  17. ↑ Sukocheva, Olga A.; Maksoud, Rebekah; Beeraka, Narasimha M.; Madhunapantula, SabbaRao V.; Sinelnikov, Mikhail; Nikolenko, Vladimir N.; Neganova, Margarita E.; Klochkov, Sergey G.; Amjad Kamal, Mohammad; Staines, Donald R; Marshall-Gradisnik, Sonya (November 26, 2021). "Analysis of post COVID-19 condition and its overlap with myalgic encephalomyelitis/chronic fatigue syndrome". Journal of Advanced Research. doi:10.1016/j.jare.2021.11.013. ISSN 2090-1232. PMC 8619886.
  18. ↑ Maksoud, Rebekah; Balinas, Cassandra; Holden, Sean; Cabanas, Hélène; Staines, Donald; Marshall-Gradisnik, Sonya (February 17, 2021). "A systematic review of nutraceutical interventions for mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome". Journal of Translational Medicine. 19 (1): 81. doi:10.1186/s12967-021-02742-4. ISSN 1479-5876. PMC 7890871. PMID 33596913.
  19. ↑ Weigel, Breanna; Eaton-Fitch, Natalie; Passmore, Rachel; Cabanas, Hélène; Staines, Donald; Marshall-Gradisnik, Sonya (June 7, 2021). "A preliminary investigation of nutritional intake and supplement use in Australians with myalgic encephalomyelitis/chronic fatigue syndrome and the implications on health-related quality of life". Food & Nutrition Research. doi:10.29219/fnr.v65.5730. ISSN 1654-661X. PMC 8254462. PMID 34262415.
  20. ↑ Eaton-Fitch, Natalie; Cabanas, Hélène; du Preez, Stanley; Staines, Donald; Marshall-Gradisnik, Sonya (July 15, 2021). "The effect of IL-2 stimulation and treatment of TRPM3 on channel co-localisation with PIP2 and NK cell function in myalgic encephalomyelitis/chronic fatigue syndrome patients". Journal of Translational Medicine. 19 (1): 306. doi:10.1186/s12967-021-02974-4. ISSN 1479-5876. PMC 8281618. PMID 34266470.
  21. ↑ Cabanas, Helene; Muraki, Katsuhiko; Eaton-Fitch, Natalie; Staines, Donald Ross; Marshall-Gradisnik, Sonya (2021). "Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment". Frontiers in Immunology. 12: 687806. doi:10.3389/fimmu.2021.687806. ISSN 1664-3224. PMC 8313851. PMID 34326841.
  22. ↑ Maksoud, Rebekah; Eaton-Fitch, Natalie; Matula, Michael; Cabanas, Hélène; Staines, Donald; Marshall-Gradisnik, Sonya (May 2021). "Systematic Review of Sleep Characteristics in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". Healthcare. 9 (5): 568. doi:10.3390/healthcare9050568.
  23. ↑ Eaton-Fitch, N.; Johnston, S.C.; Zalewski, P.; Staines, D.; Marshall-Gradisnik, S. (January 22, 2020). "Health-related quality of life in patients with myalgic encephalomyelitis/chronic fatigue syndrome: an Australian cross-sectional study". Quality of Life Research. doi:10.1007/s11136-019-02411-6. ISSN 0962-9343.
  24. ↑ Thapaliya, Kiran; Marshall-Gradisnik, Sonya; Staines, Don; Barnden, Leighton (2020). "Mapping of pathological change in chronic fatigue syndrome using the ratio of T1- and T2-weighted MRI scans". NeuroImage: Clinical. 28: 102366. doi:10.1016/j.nicl.2020.102366. PMC 7417892. PMID 32777701.
  25. ↑ Holden, Sean; Maksoud, Rebekah; Eaton-Fitch, Natalie; Cabanas, Hélène; Staines, Donald; Marshall-Gradisnik, Sonya (July 29, 2020). "A systematic review of mitochondrial abnormalities in myalgic encephalomyelitis/chronic fatigue syndrome/systemic exertion intolerance disease". Journal of Translational Medicine. 18 (1): 290. doi:10.1186/s12967-020-02452-3. ISSN 1479-5876. PMC 7392668. PMID 32727475.
  26. ↑ https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-020-02575-7
  27. ↑ Knight, Sarah; Elders, Shane; Rodda, Jill; Harvey, Adrienne; Lubitz, Lionel; Rowe, Kathy; Reveley, Colette; Hennel, Sabine; Towns, Susan; Kozlowska, Kasia; Payne, Donald N; Marshall-Gradisnik, Sonya; Scheinberg, Adam (February 23, 2019). "Epidemiology of paediatric chronic fatigue syndrome in Australia". Archives of Disease in Childhood: archdischild–2018–316450. doi:10.1136/archdischild-2018-316450. ISSN 0003-9888.
  28. ↑ Słomko, Joanna; Newton, Julia L; Kujawski, Sławomir; Tafil-Klawe, Małgorzata; Klawe, Jacek; Staines, Donald; Marshall-Gradisnik, Sonya; Zalewski, Pawel (March 2019). "Prevalence and characteristics of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) in Poland: a cross-sectional study". BMJ Open. 9 (3): e023955. doi:10.1136/bmjopen-2018-023955. ISSN 2044-6055. PMID 30850404.
  29. ↑ Cabanas, H.; Muraki, K.; Balinas, C.; Eaton-Fitch, N.; Staines, D.; Marshall-Gradisnik, S. (December 2019). "Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients". Molecular Medicine. 25 (1). doi:10.1186/s10020-019-0083-4. ISSN 1076-1551.
  30. ↑ Corbitt, Matthew; Eaton-Fitch, Natalie; Staines, Donald; Cabanas, Hélène; Marshall-Gradisnik, Sonya (December 2019). "A systematic review of cytokines in chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID)". BMC Neurology. 19 (1). doi:10.1186/s12883-019-1433-0. ISSN 1471-2377. PMID 31445522.
  31. ↑ Cabanas, Helene; Muraki, Katsuhiko; Staines, Donald; Marshall-Gradisnik, Sonya (October 14, 2019). "Naltrexone restores impaired transient receptor potential melastatin 3 ion channel function in natural killer cells from myalgic encephalomyelitis/chronic fatigue syndrome patients". Frontiers in Immunology. doi:10.3389/fimmu.2019.02545.
  32. ↑ Barnden, Leighton R; Shan, Zack Y; Staines, Donald R; Marshall-Gradisnik, Sonya; Finegan, Kevin; Ireland, Timothy; Bhuta, Sandeep (2019). "Intra brainstem connectivity is impaired in chronic fatigue syndrome". NeuroImage: Clinical. 24: 102045. doi:10.1016/j.nicl.2019.102045.
  33. ↑ Balinas, Cassandra; Cabanas, Hélène; Staines, Donald; Marshall-Gradisnik, Sonya (December 3, 2019). "Transient receptor potential melastatin 2 channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients". Journal of Translational Medicine. 17 (1): 401. doi:10.1186/s12967-019-02155-4. ISSN 1479-5876. PMC 6891975. PMID 31796045.
  34. ↑ Marshall-Gradisnik, Sonya; Fretel, Marshall; Eaton, Natalie; Cabanas, Helene; Balinas, Cassandra; Gopalan, Vinod; Petersen, Daniel; Passmore, Rachel; Tang, Kevin; Haque, Mazhar; Lam, Alfred; Staines, Donald (May 31, 2018). "Decreased Expression of TRPM3 and mAChRM3 in the Small Intestine in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis". International Journal of Clinical Medicine. 09 (05): 467. doi:10.4236/ijcm.2018.95040.
  35. ↑ Shan, Zack Y.; Finegan, Kevin; Bhuta, Sandeep; Ireland, Timothy; Staines, Donald R.; Marshall‐Gradisnik, Sonya; Barnden, Leighton R. (2018), "Brain function characteristics of chronic fatigue syndrome: A task fMRI study", NeuroImage: Clinical, 19: 279-286, doi:10.1016/j.nicl.2018.04.025
  36. ↑ Corbitt, M; Campagnolo, N; Staines, D; Marshall-Gradisnik, S (2018), "A Systematic Review of Probiotic Interventions for Gastrointestinal Symptoms and Irritable Bowel Syndrome in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)", Probiotics Antimicrob Proteins, doi:10.1007/s12602-018-9397-8
  37. ↑ Du Preez, S.; Corbitt, M.; Cabanas, H.; Eaton, N.; Staines, D.; Marshall-Gradisnik, S. (December 20, 2018). "A systematic review of enteric dysbiosis in chronic fatigue syndrome/myalgic encephalomyelitis". Systematic Reviews. 7 (1): 241. doi:10.1186/s13643-018-0909-0. ISSN 2046-4053. PMID 30572962.
  38. ↑ Eaton, Natalie; Cabanas, Hélène; Balinas, Cassandra; Klein, Anne; Staines, Donald; Marshall-Gradisnik, Sonya (December 2018). "Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation". BMC Pharmacology and Toxicology. 19 (1): 12. doi:10.1186/s40360-018-0203-8. ISSN 2050-6511. PMC 5870391. PMID 29587879.
  39. ↑ Nguyen, T.; Staines, D.; Johnston, S.; Marshall-Gradisnik, S. (July 2018), "Reduced glycolytic reserve in isolated natural killer cells from Myalgic encephalomyelitis/chronic fatigue syndrome patients: A preliminary investigation", Asian Pac J Allergy Immunol, doi:10.12932/AP-011117-0188
  40. ↑ Barnden, Leighton R.; Shan, Zack Y.; Staines, Donald R.; Marshall-Gradisnik, Sonya; Finegan, Kevin; Ireland, Timothy; Bhuta, Sandeep (2018). "Hyperintense sensorimotor T1 spin echo MRI is associated with brainstem abnormality in chronic fatigue syndrome". NeuroImage: Clinical. 20: 102–109. doi:10.1016/j.nicl.2018.07.011.
  41. ↑ Cabanas, Hélène; Muraki, Katsuhiko; Eaton, Natalie; Balinas, Cassandra; Staines, Donald; Marshall-Gradisnik, Sonya (August 14, 2018). "Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients". Molecular Medicine. 24 (1). doi:10.1186/s10020-018-0046-1. ISSN 1076-1551.
  42. ↑ Shan, Zack Y.; Finegan, Kevin; Bhuta, Sandeep; Ireland, Timothy; Staines, Donald R.; Marshall-Gradisnik, Sonya M.; Barnden, Leighton R. (February 2018). "Decreased Connectivity and Increased Blood Oxygenation Level Dependent Complexity in the Default Mode Network in Individuals with Chronic Fatigue Syndrome". Brain Connectivity. 8 (1). doi:10.1089/brain.2017.0549.
  43. ↑ Campagnolo, N.; Johnston, S.; Collatz, A.; Staines, D.; Marshall-Gradisnik, S. (January 22, 2017). "Dietary and nutrition interventions for the therapeutic treatment of chronic fatigue syndrome/myalgic encephalomyelitis: a systematic review". Journal of Human Nutrition and Dietetics. 30 (3): 247–259. doi:10.1111/jhn.12435. ISSN 0952-3871. PMID 28111818.
  44. ↑ Nguyen, T.; Hardcastle, S.; Clarke, L.; Smith, P.; Staines, D.; Marshall-Gradisnik, S. (2017), "Impaired calcium mobilization in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients is associated with transient receptor potential melastatin 3 ion channels", Clinical and Experimental Immunology, 187 (2): 284–293, doi:10.1111/cei.12882
  45. ↑ Nguyen, T.; Johnston, S.; Chacko, A.; Gibson, D.; Cepon, J.; Smith, D.; Staines, D.; Marshall-Gradisnik, S. (2017), "Novel characterisation of mast cell phenotypes from peripheral blood mononuclear cells in chronic fatigue syndrome/myalgic encephalomyelitis patients", Asian Pac J Allergy Immunol, 35 (2): 75-81, doi:10.12932/AP0771
  46. ↑ Huth, Teilah K.; Staines, Donald; Marshall-Gradisnik, Sonya (2016), "ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56dimCD16+ and CD56brightCD16dim/− natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients", Journal of Translational Medicine, 14 (97), doi:10.1186/s12967-016-0859-z
  47. ↑ Marshall-Gradisnik, Sonya M.; Huth, Teilah; Chacko, Anu; Johnston, Samantha; Smith, Peter; Staines, Donald R. (2016), "Natural killer cells and single nucleotide polymorphisms of specific ion channels and receptor genes in myalgic encephalomyelitis/chronic fatigue syndrome", The Application of Clinical Genetics, 9: 39—47, doi:10.2147/TACG.S99405
  48. ↑ Collatz, Ansel; Johnston, Samantha C.; Staines, Donald R.; Marshall-Gradisnik, Sonya M. (2016), "A Systematic Review of Drug Therapies for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis", Clinical Therapeutics, 38 (6): 1263-1271.e9, doi:10.1016/j.clinthera.2016.04.038, PMID 27229907
  49. ↑ Shan, Zack Y.; Kwiatek, Richard; Burnet, Richard; Del Fante, Peter; Staines, Donald R.; Marshall‐Gradisnik, Sonya; Barnden, Leighton R. (2016), "Progressive brain changes in patients with chronic fatigue syndrome: A longitudinal MRI study", Journal of Magnetic Resonance Imaging, 44: 1301–1311, doi:10.1002/jmri.25283
  50. ↑ Ramos, S; Brenu, E; Broadley, S; Kwiatek, R; Ng, J; Nguyen, T; Freeman, S; Staines, D; Marshall-Gradisnik, S (March 20, 2016), "Regulatory T, natural killer T and γδ T cells in multiple sclerosis and chronic fatigue syndrome/myalgic encephalomyelitis: a comparison" (PDF), Asian Pac J Allergy Immunol, 2016 (34): 300-305, doi:10.12932/AP0733
  51. ↑ Huth, T.K.; Brenu, E.W.; Staines, D.R.; Marshall-Gradisnik, S.M. (2016), "Killer Cell Immunoglobulin-like Receptor Genotype and Haplotype Investigation of Natural Killer Cells from an Australian Population of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients", Gene Regulation and Systems Biology, 10: 43–49, doi:10.4137/GRSB.S39861
  52. ↑ Wong, Naomi; Nguyen, Thao; Brenu, Ekua Weba; Broadley, Simon; Staines, Donald; Marshall-Gradisnik, Sonya (2015), "A Comparison of Cytokine Profiles of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis Patients", International Journal of Clinical Medicine, 6 (10): 769-783, doi:10.4236/ijcm.2015.610103
  53. ↑ Peterson, D; Brenu, EW; Gottschalk, G; Ramos, Sandra B; Nguyen, T; Staines, D; Marshall-Gradisnik, S (2015), "Cytokines in the Cerebrospinal Fluids of Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis", Mediators of Inflammation, 2015, doi:10.1155/2015/929720
  54. ↑ Hardcastle, SL; Brenu, EW; Johnston, S; Nguyen, T; Huth, T; Wong, N; Ramos, S; Staines, DR; Marshall-Gradisnik, SM (2015), "Serum Immune Proteins in Moderate and Severe Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients", International Journal of Medical Sciences, 12 (10): 764-772, doi:10.7150/ijms.12399
  55. ↑ Hardcastle, Sharni Lee; Brenu, Ekua Weba; Johnston, Samantha; Nguyen, Thao; Huth, Teilah; Ramos, Sandra; Staines, Donald; Marshall-Gradisnik, Sonya (2015), "Longitudinal analysis of immune abnormalities in varying severities of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients", Journal of Translational Medicine, 13 (299), doi:10.1186/s12967-015-0653-3
  56. ↑ Hardcastle, SL; Brenu, EW; Johnston, S; Nguyen, T; Huth, T; Wong, N; Ramos, S; Staines, DR; Marshall-Gradisnik, SM (2015), "Characterisation of cell functions and receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)", BMC Immunology, 16 (35), doi:10.1186/s12865-015-0101-4
  57. ↑ Marshall-Gradisnik, Sonya M.; Smith, Peter; Brenu, Ekua W.; Nilius, Bernd; Ramos, Sandra B.; Staines, Donald R. (2015), "Examination of Single Nucleotide Polymorphisms (SNPs) in Transient Receptor Potential (TRP) Ion Channels in Chronic Fatigue Syndrome Patients", Immunology and Immunogenetics Insights, 2015 (7): 1-6, doi:10.4137/III.S25147
  58. ↑ Huth, Teilah K.; Brenu, Ekua; Nguyen, Thao; Hardcastle, Sharni L.; Johnston, Samantha; Ramos, Sandra; Staines, Donald R.; Marshall-Gradisnik, Sonya M. (2014), "Characterization of Natural Killer Cell Phenotypes in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis", Journal of Clinical & Cellular Immunology, 5 (3), doi:10.4172/2155-9899.1000223
  59. ↑ Brenu, EW; Huth, TK; Hardcastle, SL; Fuller, K; Kaur, M; Johnston, S; Ramos, S; Staines, D; Marshall-Gradisnik, S (2014), "The Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis", International Immunology, 26 (4): 233-42, doi:10.1093/intimm/dxt068, PMID 24343819
  60. ↑ Hardcastle, Sharni L.; Brenu, Ekua W.; Johnston, Samantha; Nguyen, Thao; Huth, Teilah K.; Kaur, Manprit; Ramos, Sandra; Salajegheh, Ali; Staines, Donald R.; Marshall-Gradisnik, Sonya (2014), "Analysis of the Relationship between Immune Dysfunction and Symptom Severity in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)", Journal of Clinical & Cellular Immunology, 5 (190), doi:10.4172/2155-9899.1000190
  61. ↑ Johnston, S.C.; Brenu, E.W.; Staines, D.R.; Marshall-Gradisnik, S.M. (2013), "The role of clinical guidelines for chronic fatigue syndrome/myalgic encephalomyelitis in research settings.", Fatigue: Biomedicine, Health & Behavior, 2 (1): 28-39, doi:10.1080/21641846.2013.860779
  62. ↑ Brenu, Ekua W; van Driel, Mieke L; Staines, Donald R; Kreijkamp-Kaspers, Sanne; Hardcastle, Sharni L; Marshall-Gradisnik, Sonya M (2012). "The Effects of Influenza Vaccination on Immune Function in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis" (PDF). International Journal of Clinical Medicine. 3 (6): 544-551. doi:10.4236/ijcm.2012.36098.
  63. ↑ Brenu, Ekua W; van Driel, Mieke L; Staines, Don R; Ashton, Kevin J; Ramos, Sandra B; Keane, James; Klimas, Nancy G; Marshall-Gradisnik, Sonya M (2011). "Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis". Journal of Translational Medicine. 9 (1): 81. doi:10.1186/1479-5876-9-81. ISSN 1479-5876. PMC 3120691. PMID 21619669.

See ME/CFS.

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

mitochondria Important parts of the biological cell, with each mitochondrion encased within a mitochondrial membrane. Mitochondria are best known for their role in energy production, earning them the nickname "the powerhouse of the cell". Mitochondria also participate in the detection of threats and the response to these threats. One of the responses to threats orchestrated by mitochondria is apoptosis, a cell suicide program used by cells when the threat can not be eliminated.

systemic exertion intolerance disease (SEID) - A term for ME/CFS that aims to avoid the stigma associated with the term "chronic fatigue syndrome", while emphasizing the defining characteristic of post-exertional malaise (PEM). SEID was defined as part of the diagnostic criteria put together by the Institute of Medicine (IOM) report of 10 February 2015.

See systemic exertion intolerance disease.

Region of the midbrain in adults, includes midbrain, pons, and medulla oblongata and develops.[1]

brainstem Region of the midbrain in adults, includes midbrain, pons, and medulla oblongata and develops.

single nucleotide polymorphism (SNP) - A single nucleotide polymorphism (SNP, pronounced "snip") is a potential genetic mutation that occurs in a single spot in the human genome; a difference in a single DNA building block. SNPs are often represented by an "rs" number, such as "rs53576".

T cell A type of white blood cell which is mostly produced or matured in the thymus gland (hence T-cell) and is involved in the adaptive immune response on a cellular level. Also known as a T lymphocyte. (Learn more: www.youtube.com)

antibodies Antibody/immunoglobulin refers to any of a large number of specific proteins produced by B cells that act against an antigen in an immune response.

serum The clear yellowish fluid that remains from blood plasma after clotting factors have been removed by clot formation. (Blood plasma is simply blood that has had its blood cells removed.)

single nucleotide polymorphism (SNP) - A single nucleotide polymorphism (SNP, pronounced "snip") is a potential genetic mutation that occurs in a single spot in the human genome; a difference in a single DNA building block. SNPs are often represented by an "rs" number, such as "rs53576".

The BMJ (previously the British Medical Journal) is a weekly peer-reviewed medical journal.

BMJ The BMJ (previously the British Medical Journal) is a weekly peer-reviewed medical journal.

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

cytokine any class of immunoregulatory proteins secreted by cells, especially immune cells. Cytokines are small proteins important in cell signaling that modulate the immune system. (Learn more: me-pedia.org)

cytokine any class of immunoregulatory proteins secreted by cells, especially immune cells. Cytokines are small proteins important in cell signaling that modulate the immune system. (Learn more: me-pedia.org)

Retrieved from "https://me-pedia.org/w/index.php?title=Sonya_Marshall-Gradisnik&oldid=240434"